Sales of Pfizer's pneumococcal vaccine Prevenar 13 fell by half year-on-year in the first quarter. Although sales soared after the spread of Covid-19 last year, it seems to have returned to the previous year's level this year.

According to IQVIA, a pharmaceutical research institute on the 24th, Prevenar 13's sales in the first quarter fell 46.7% year-on-year to ₩9.4 billion. It shrank from $17.6 billion in the first quarter of last year to half in a year. Compared to ₩21.1 billion in the fourth quarter of last year, sales decreased by 55.5% in the first quarter.

Prevenar 13 posted quarterly sales of around ₩10 billion. It broke sales record in first quarter of last year